AXSOME THERAPEUTICS INC. - COMMON STOCK

Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor

01 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

19 Aug 2022 05:45:03 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

09 Aug 2022 06:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

28 Jul 2022 06:00:02 By Nasdaq GlobeNewswire

Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders

28 Jun 2022 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event

22 Jun 2022 06:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting

06 Jun 2022 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder

02 Jun 2022 06:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting

01 Jun 2022 06:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry

31 May 2022 06:39:37 By Nasdaq GlobeNewswire

Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

09 May 2022 07:57:19 By Nasdaq GlobeNewswire

Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience

28 Mar 2022 05:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Participate in the 1st Annual Needham Virtual Neuroscience Forum

11 Mar 2022 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

02 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

01 Mar 2022 06:00:02 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

15 Feb 2022 06:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

11 Feb 2022 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

08 Nov 2021 06:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021

20 Oct 2021 06:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million

18 Oct 2021 06:00:00 By Nasdaq GlobeNewswire